Northern Trust’s Vigil Neuroscience VIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-71,588
| Closed | -$569K | – | 4545 |
|
|
2025
Q2 | $569K | Buy |
71,588
+10,469
| +17% | +$46.9K | ﹤0.01% | 3609 |
|
|
2025
Q1 | $109K | Sell |
61,119
-3,618
| -6% | -$8.12K | ﹤0.01% | 4093 |
|
|
2024
Q4 | $110K | Buy |
64,737
+14,572
| +29% | +$43K | ﹤0.01% | 4136 |
|
|
2024
Q3 | $171K | Sell |
50,165
-83,438
| -62% | -$309K | ﹤0.01% | 3925 |
|
|
2024
Q2 | $534K | Sell |
133,603
-5,117
| -4% | -$17.5K | ﹤0.01% | 3486 |
|
|
2024
Q1 | $473K | Sell |
138,720
-2,681
| -2% | -$8.37K | ﹤0.01% | 3581 |
|
|
2023
Q4 | $478K | Buy |
141,401
+15,667
| +12% | +$80.6K | ﹤0.01% | 3549 |
|
|
2023
Q3 | $678K | Buy |
125,734
+1,372
| +1% | +$9.48K | ﹤0.01% | 3428 |
|
|
2023
Q2 | $1.17M | Buy |
124,362
+102,127
| +459% | +$966K | ﹤0.01% | 3297 |
|
|
2023
Q1 | $218K | Buy |
22,235
+3,441
| +18% | +$38.7K | ﹤0.01% | 3821 |
|
|
2022
Q4 | $235K | Buy |
18,794
+6,712
| +56% | +$82.4K | ﹤0.01% | 3794 |
|
|
2022
Q3 | $110K | Hold |
12,082
| – | – | ﹤0.01% | 4084 |
|
|
2022
Q2 | $31K | Sell |
12,082
-44,601
| -79% | -$176K | ﹤0.01% | 4547 |
|
|
2022
Q1 | $398K | Buy |
+56,683
| New | +$748K | ﹤0.01% | 3833 |
|
Other funds holding VIGL
Northern Trust's VIGL Position: Q3 2025 in Review
Northern Trust sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 71,588 shares — an estimated $569K sold.
Northern Trust first reported a position in VIGL in Q1 2022 and held it in 14 quarters. The position peaked at $1.17M in Q2 2023. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.
- Northern Trust reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
- Northern Trust sold 71,588 Vigil Neuroscience shares in Q3 2025, an estimated $569K.
- Northern Trust first reported a position in Vigil Neuroscience in Q1 2022 and held it in 14 quarters.
- Northern Trust's Vigil Neuroscience position peaked at $1.17M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.
Based on Northern Trust's 13F filing for Q3 2025, filed 14 Nov 2025.